CRMD vs PRAX vs ACAD vs NKTR

For growth investors, CorMedix Inc.

(CRMD) is the stronger pick with 617. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). CorMedix Inc. (CRMD) offers the better valuation at 3. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate CorMedix Inc. (CRMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CorMedix Inc.

(CRMD) is the cheapest at 3. 9x versus ACADIA Pharmaceuticals Inc. at 9. 8x. On forward P/E, CorMedix Inc. is actually cheaper at 14. 2x.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of +6. 6%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus NKTR's -59. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 11β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 62% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CorMedix Inc.

(CRMD) is pulling ahead at 617. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: CorMedix Inc. grew EPS 780. 0% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, CRMD leads at 1583% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CorMedix Inc.

(CRMD) is the more profitable company, earning 52. 3% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 52. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRMD leads at 48. 2% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CorMedix Inc.

(CRMD) trades at 14. 2x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 41. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 79. 9% to $147. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -23. 4%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CRMD is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; NKTR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.